References
- Remes J., Miettinen H., Reunanen A., Pyorala K. Validity of clinical diagnosis of heart failure in primary health care. Eur Heart J 1991; 12: 315–21
- Redfield M. M., Jacobsen S. J., Burnett J. C, Jr., et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003; 289: 194–202
- Sudoh T., Kangawa K., Minamino N., Matsuo H. A new natriuretic peptide in porcine brain. Nature 1988; 332: 78–81
- Mukoyama M., Nakao K., Hosoda K., et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991; 87: 1402–12
- Bruneau B. G., Piazza L. A., De Bold A. J. BNP gene expression is specifically modulated by stretch and ET‐1 in a new model of isolated rat atria. Am J Physiol 1997; 273: H2678–86
- Hunt P. J., Richards A. M., Nicholls M. G., et al. Immunoreactive amino‐terminal pro‐brain natriuretic peptide (NT‐PROBNP): a new marker of cardiac impairment. Clin Endocrinol (Oxf) 1997; 47: 287–96
- Omland T., Aakvaag A., Vik‐Mo H. Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment. Heart 1996; 76: 232–7
- Luchner A., Hengstenberg C., Lowel H., et al. N‐terminal pro‐brain natriuretic peptide after myocardial infarction: a marker of cardio‐renal function. Hypertension 2002; 39: 99–104
- Pemberton C. J., Johnson M. L., Yandle T. G., Espiner E. A. Deconvolution analysis of cardiac natriuretic peptides during acute volume overload. Hypertension 2000; 36: 355–9
- Johnson W., Omland T., Hall C., et al. Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. J Am Coll Cardiol 2002; 39: 1623–9
- Downie P. F., Talwar S., Squire I. B., et al. Assessment of the stability of N‐terminal pro‐brain natriuretic peptide in vitro: implications for assessment of left ventricular dysfunction. Clin Sci (Lond) 1999; 97: 255–8
- Muders F., Kromer E. P., Griese D. P., et al. Evaluation of plasma natriuretic peptides as markers for left ventricular dysfunction. Am Heart J 1997; 134: 442–9
- Daggubati S., Parks J. R., Overton R. M., et al. Adrenomedullin, endothelin, neuropeptide Y, atrial, brain, and C‐natriuretic prohormone peptides compared as early heart failure indicators. Cardiovasc Res 1997; 36: 246–55
- Yandle T., Fisher S., Espiner E., Richards M., Nicholls G. Validating aminoterminal BNP assays: a word of caution. Lancet 1999; 353: 1068–9
- McGeoch G., Lainchbury J., Town G. I., et al. Plasma brain natriuretic peptide after long‐term treatment for heart failure in general practice. Eur J Heart Fail 2002; 4: 479–83
- Tang W. H., Girod J. P., Lee M. J., et al. Plasma B‐type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure. Circulation 2003; 108: 2964–6
- Raymond I., Groenning B. A., Hildebrandt P. R., et al. The influence of age, sex and other variables on the plasma level of N‐terminal pro brain natriuretic peptide in a large sample of the general population. Heart 2003; 89: 745–51